DISCOVER MYTOMORROWS. EARLY ACCESS TO DRUGS IN DEVELOPMENT.

DISCOVER EXPANDED ACCESS PROGRAMS

myTomorrows provides physicians and patients that are excluded from clinical trials access to drugs in development. We focus on disease areas with unmet needs; oncology, neurology, psychiatry and rare diseases.

Create your free account as Patient, HealthCare Professional, Pharmacist or Friend & Family to receive information about our Expanded Access Programs:

CREATE MY ACCOUNT

YOUR PLACE FOR EXPANDED ACCESS PROGRAMS

Find Programs for oncology, neurology, psychiatry and rare diseases on our platform.

SEE ALL PROGRAMS

expanded access programs

WHAT WE DO

Identify drug developments. Our physicians and bio-medical specialists identify the latest drug developments from across the globe.

Inform. Physicians and pharmacists can register online and request information about the drugs myTomorrows provides access to.

Facilitate requests. In most countries health authorities must grant permission for treatment with a non-registered drug. myTomorrows facilitates requests for permission for physicians and pharmacists.

WHO WE ARE

myTomorrows was founded by physicians and experts from the pharmaceutical industry who want to facilitate early access to drugs in development for patients with high unmet needs, who are excluded from clinical trials. A newspaper article quote from an ALS patient needing access to not-yet-registered drugs was the inspiration for the company’s name: “I just want some more tomorrows”.

OUR MOTIVATION

Imagine. One of your relatives or friends is seriously ill and cannot be treated with available drugs. Some of the founders have been through this ordeal. Seriously ill patients are increasingly aware of the drug developments in their disease area. Sometimes patients can participate in clinical trials, but more often they cannot. For these patients and their physicians, myTomorrows is building a bridge to drug developers.

DISCOVER MYTOMORROWS

SEE ALL PROGRAMS

WHAT ARE EXPANDED ACCESS PROGRAMS?

Drug development takes about twelve years from discovery to marketing authorization. Drugs that show promising results during clinical development need to be tested in large patient populations before receiving marketing authorization. In many cases patients with high unmet medical needs that are excluded from clinical trials, can’t afford to wait the extra years it takes for a drug to receive such a marketing authorization.

Expanded Access Programs enable physicians and patients who have exhausted other medicinal treatment options to access development stage drugs or drugs that have marketing authorization elsewhere, but not yet in their home country.

LEARN MORE...

dna sequencing genome

BUILDING THE MOST COMPLETE EXPANDED ACCESS PROGRAM DATABASE IN THE WORLD

Search Made Easy

Searching expanded access programd and clinical trials has never been so simple with the myTomorrows Mobile app.

It is free…

IN THE PRESS